Vitae Research Center, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$623,519	2
2024	Research	$172,985	1
2021	Research	$12,236	1
2020	Research	$36,677	2
2019	Research	$274,145	8

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $796,504 3 payments
Avanir Pharmaceuticals, Inc. $323,058 11 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $623,519 2 payments
15-Avp-786-303 $198,424 7 payments
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $172,985 1 payment
15-Avp-786-301 $124,634 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.